Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

Overview of attention for article published in Journal of Hematology & Oncology, January 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

So far, Altmetric has seen 1 X post from an account with 37 followers.

MK-2206, oral AKT inhibitor advanced solid tumors. Phase 1 trial, NCT00848718, http://t.co/3RChBD468M

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.